 |
|
Signaling Networks in Cutaneous Melanoma Metastasis Identified by Complementary DNA Microarrays
Sandeep Nambiar, PhD;
Alireza Mirmohammadsadegh, PhD;
Roya Doroudi, PhD;
Annett Gustrau, BA;
Alessandra Marini, MD;
Gernot Roeder, PhD;
Thomas Ruzicka, MD;
Ulrich R. Hengge, MD
Arch Dermatol. 2005;141:165-173.
Background Melanoma is a complex multigenic disease, susceptibility to which is determined by several parallel and stepwise progressive pathways affecting growth control, differentiation, cell adhesion, and survival. Melanoma and human cancers in general undergo a continuous development from benign to malignant states, as most thoroughly documented in the multistep mole-to-melanoma transition.
Objective To examine how high-throughput microarrays are being used in expression profiling to identify regulated genes, patterns, and pathways that may lead to functional characterization and tumor subclassification.
Design Ten melanoma metastases were analyzed by DNA array technology for important regulated candidate genes, with subsequent confirmation by real-time reverse transcription polymerase chain reaction.
Results Hepatocyte growth factor receptor c-met, growth factor receptor–bound protein 10, B-raf proto-oncogene, and several mitogen-activated protein kinase kinase genes were significantly up-regulated in melanoma metastases and several melanoma cell lines relative to normal human melanocytes (P = .03). Among the up-regulated genes, phosphorylated growth factor receptor–bound protein 10 is known to serve a molecular switch turning on the mitogen-activated protein kinase pathway in response to hepatocyte growth factor receptor binding.
Conclusions As suggested by the DNA arrays, we found the mitogen-activated protein kinase kinase/extracellular-regulated kinase pathway to be activated in most of the cutaneous melanoma metastasis specimens. These findings are in the context of the current microarray technology in melanoma research. Additional steps are needed to gain insights into the pluralistic signaling milieu of this malignancy as we enter the postgenomic era.
Author Affiliations: Department of Dermatology (Drs Nambiar, Mirmohammadsadegh, Doroudi, Marini, Ruzicka, and Hengge and Ms Gustrau) and Institute of Clinical Oncology (Dr Roeder), Heinrich-Heine-University, Düsseldorf, Germany.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLES
A Search for CDKN2A/p16INK4a Mutations in Melanocytic Nevi From Patients With Melanoma and Spouse Controls by Use of Laser-Captured Microdissection
Hao Wang, Richard B. Presland, and Michael Piepkorn
Arch Dermatol. 2005;141(2):177-180.
ABSTRACT
| FULL TEXT
Two Frameshift Mutations in the RNA-Specific Adenosine Deaminase Gene Associated With Dyschromatosis Symmetrica Hereditaria
Min Gao, Pei-Guang Wang, Sen Yang, Xiao-Li Hu, Kai-Yue Zhang, Ya-Gang Zhu, Yun-Qing Ren, Wen-Hui Du, Guo-Long Zhang, Yong Cui, Jian-Jun Chen, Kai-Lin Yan, Feng-Li Xiao, Shi-Jie Xu, Wei Huang, and Xue-Jun Zhang
Arch Dermatol. 2005;141(2):193-196.
ABSTRACT
| FULL TEXT
Molecular Diagnosis of Cutaneous Diseases
Karan K. Sra, Michelle Babb-Tarbox, Sina Aboutalebi, Peter Rady, Gregory L. Shipley, Dat D. Dao, and Stephen K. Tyring
Arch Dermatol. 2005;141(2):225-241.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation
Tormo et al.
Am. J. Pathol. 2006;169:665-672.
ABSTRACT
| FULL TEXT
Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
Belhocine et al.
JNM 2006;47:957-967.
ABSTRACT
| FULL TEXT
Biotechnology Succeeds in Revolutionizing Medical Science
Robinson and Callen
Arch Dermatol 2005;141:133-134.
FULL TEXT
|
